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Abstract: Introduction: The purpose of this study was to separate MAC lung disease from colonization and to define 
indications for treatment. 
Materials and Methodology: Over 4 years, we evaluated patients who had positive MAC cultures, MAC infection and co-
infection with MTB. In the first study, 42 immunocompetent patients with sputum or BAL culture positive only for MAC 
during a single year (2004) were reviewed. On clinical and radiographic review, they were classified as disease related to 
MAC, likely related to MAC or unrelated to MAC. In the second study, we reviewed all immunocompetent patients, 
during two years (2004-2005), whose respiratory secretions cultured both MTB and nontuberculous mycobacteria (NTM). 
In the last study, we evaluated pulmonary function (PF) in patients with MAC infection before and after therapy (2006-
2007). PF was evaluated in patients following ATS guidelines. 
Results: Lung disease was related/likely related to MAC in 21 patients (50%) and not related in 21 (50%). In patients with 
MAC-related lung disease, the primary physician did not consider the diagnosis except when that physician was a 
pulmonologist. Half of those with MAC-related lung disease were smokers, white and US-born. There were 12 
immunocompetent patients with MTB and NTM cultures. Eleven were non-white and all were foreign-born. Presentation 
and clinical course were consistent with MTB. All 8 patients with abnormal PF improved. 
Conclusions: The prevalence of MAC lung infection in two inner city hospitals was four times higher than that of TB. The 
indication for treatment of MAC infection should also rely heavily on clinical and radiological evidence when there is 
only one positive sputum culture. The diagnosis was considered only when the admitting physician was a pulmonologist. 
Most patients with combined infection were clinically consistent with MTB and responded to anti MTB treatment alone. 
Treatment with anti-MAC therapy improved PF in those patients whose PF was abnormal to begin with. 
Keywords:  Mycobacterium avium complex (MAC), Mycobacterium tuberculosis (MTB), Non-Tuberculous mycobacteria 
(NTM), immunocompetent, bronchoalveolar lavage (BAL), bronchiectasis, cavitation, Bacillus Calmette-Guerin (BCG) 
vaccination, pulmonary function (PF). 
INTRODUCTION 
  MAC is a ubiquitous environmental microorganism. It is 
found in water, soil and even in cigarette components 
including tobacco, filter and paper [1]. It can be a laboratory 
contaminant, causing sporadic positive cultures. 
  This organism can cause disease in both immunocompe-
tent and immunocompromised persons. In recent years, there 
has been an increase in disease incidence; it is not clear 
whether this reflects a real increase in infections or greater 
recognition resulting from more widespread awareness and 
more sensitive laboratory techniques [2]. 
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  Lung disease caused by MAC was first described in 
sanatorium patients with suspected tuberculosis [3]. Before 
1989, MAC disease was thought to be limited to elderly men 
with a history of alcohol and tobacco use and pre-existing 
lung disease. In 1989, Prince et al. found that fibronodular 
bronchiectasis was common in MAC infection of the lung, 
often seen in elderly women without underlying lung disease 
or immunosuppression [4]. In women, MAC infection 
mainly affects the middle lobe and lingula. In men, it affects 
the upper lobes, which may show fibrocavitary disease. 
  Studies by Beck, 1959 and Warring, 1968 showed that 
MAC infection may be present for months or years before 
diagnosis is made [5, 6]. Some patients may be 
asymptomatic and come to diagnosis as an incidental x-ray 
finding. Many patients have chronic productive cough often 
attributed to COPD but usually without hemoptysis, fever, 
night sweats, weight loss, malaise, lethargy and fatigue 
unless there is extensive lung disease [7]. MAC Lung Disease in Inner City Community Hospitals  The Open Respiratory Medicine Journal, 2010, Volume 4    77 
 Mycobacterium Tuberculosis (MTB) and Non-
Tuberculous Mycobacteria (NTM) lung infection often 
resemble each other. We were unaware of how often these 
organisms co-exist in our institution. 
  Physicians are often conflicted whether to treat patients 
with MAC since symptoms are often minimal or nonspecific 
and treatment is prolonged and associated with side effects. 
Many of these patients have abnormal pulmonary function 
(PF), which can precede or result from MAC infection. 
Expected improvements in PF would be an indication to 
treat. 
  The purpose of our study is to evaluate the prevalence 
and nature of MAC infection, MAC co-infection with MTB 
and pulmonary function before and after treatment, in Mary 
Immaculate and Saint John’s hospitals, two inner city 
hospitals, in Queens, New York. These hospitals served a 
diverse patient population including a majority of foreign-
born, black, Asian and Hispanic patients. Most of these 
patients were generally on Medicaid or lacking insurances. 
MATERIALS AND METHODOLOGY 
  For the studies, we reviewed medical and mycobacterio-
logy laboratory records, chest x-rays and/or computer 
tomography (CT) scans, Department of Health Registry and 
Pulmonary Function Laboratory data from 2004 to 2007. 
The initial purpose of the study was to assess the incidence 
and likelihood of diagnosis of MAC-related lung disease, in 
immunocompetent and in immunocompromised patients, in 
two inner city hospitals, and compare this incidence with that 
of tuberculosis and of co-infection. As an outgrowth of these 
efforts, we noted that pulmonary function was impaired in 
many patients and questioned whether treating MAC would 
improve function. 
  For the first part of this study, all patients’ whose 
respiratory secretions grew MAC during the year 2004 were 
evaluated. Immunocompromised patients and those who had 
active tuberculosis were excluded. Each case was classified 
as having lung disease (a) related, (b) likely related, or (c) 
unrelated to MAC infection. The patients were categorized 
based on the presence or absence of :(1) Clinical evidence of 
a chronic disease characterized by otherwise unexplained 
cough, sputum, weight loss and/ or fever; (2) otherwise 
unexplained radiographic findings including peripheral 
nodules with or without cavitation and bronchiectasis; (3) 
lack of response to standard respiratory antibiotics; (4) 
appropriate response to antibiotic regimen for MAC. 
  For the second part of this study, we evaluated all 
immunocompetent patients whose respiratory secretions 
cultured positive for either or both MTB and NTM during 
2004 and 2005. 
  In the third part of this study, we reviewed the medical 
records of 10 patients who received standard MAC 
treatment, from 2006-2007. Nine patients completed at least 
12 months of anti-MAC therapy and one patient who was 
unable to tolerate therapy completed 5 months. Treatment 
followed ATS guidelines [7]. Spirometry pre and post 
bronchodilator
  (BD) was obtained for all patients. Lung 
volumes and DLCO were obtained
  for 5 patients. Percent 
predicted values for FEV1 and FVC were
 used to monitor 
changes. The largest values for FEV1, FVC and FEV1/FVC
 
either pre or post BD were used.
 Miller’s predicted values 
were used [8, 9]. The student’s t-test was used for statistical 
analysis. 
RESULTS 
  For the first study, at least one respiratory culture was 
positive for MAC in 89 patients. Ten cases were excluded 
because of insufficient clinical information. Another 32 
patients were immunocompromised due to malignant 
disease, HIV positivity (29), or treatment with steroids or 
cytostatic drugs. Another 5 patients were excluded for 
coexisting active pulmonary tuberculosis. The remaining 42 
patients were the subjects of detailed clinical-radiological 
review. Fig. (1) summarizes these results. 
  Thirteen patients (31%) had disease related to MAC 
based on typical clinical and radiographic features: 
bronchiectasis in 2 patients, cavitary disease in 1 patient, 
nodules in 3 patients and diffuse densities in 3 patients; 4 
patients had a combination of bronchiectasis, infiltrate and 
nodules. Sex distribution was almost equal; age ranged from 
48 to 77 years. In this group, 77% had pre-existing lung 
disease and 46% smoked. 2 patients had only one MAC 
positive sputum; one had only 1 sample sent while the other 
had 2 samples sent. The possibility of MAC related lung 
disease was never considered by the primary attending 
physician except when that physician was a pulmonologist; 
pulmonary or Infectious Disease consultation was not 
sought. Three of the 13 patients, whose private medical 
doctor (PMD) were pulmonologists, diagnosis were 
confirmed with response to appropriate anti-MAC treatment 
started on admission. Three patients were treated, in the 
pulmonary clinics after discharge. Six patients were follow-
up at other institutions/offices and one patient die before 
treatment with anti-MAC was started. These 7 patients had 
consistent clinical and radiographic findings for MAC lung 
disease. All patients had monthly sputum culture for MAC 
while on treatment. Figs. (2, 3) shows the CT scans of two of 
the patients who had lung disease related to MAC. 
  There were eight (8) patients (19%) who had lung 
abnormalities likely related to MAC. Confirmation could not 
be obtained since these patients were lost to long-term 
follow up. Of these, 4 patients had only one sputum MAC 
positive (only one sputum sample was sent for all 4 patients). 
LUNG DISEASE NOT RELATED TO MAC (21 
PATIENTS) 
  Twenty-one patients (50%) who had one or more cultures 
positive for MAC had a lung disease clearly not related to 
MAC. Most of these patients were admitted for typical 
clinical and radiographic findings of community acquired 
pneumonia that resolved rapidly. In this group, 10 patients 
had only one sputum MAC positive (3 patients had 1 of 3 
sputum samples and 7 had only one sputum sample sent). 
One patient had 5 sputum samples positive for MAC. 
  For the second study, on co-infection with MTB, thirty-
one (31) patients were positive for MTB alone of whom 11 
were immunocompetent; 92 immunocompetent patients were 
positive for MAC alone. Eighteen (18) patients were positive 
for both MTB and NTM, 12 of whom were 
immunocompetent. Eight of these twelve patients were 
positive for MTB and MAC. The other four patients were 78    The Open Respiratory Medicine Journal, 2010, Volume 4  Khan et al. 
positive for MTB and other non NTM. Of the twelve dual-
infected patients, age range was 20-68 years. Eight were 
men, 8 were smokers and 8 patients did not have any 
previous diseases. Their length of hospital stay varied from 6 
to 50 days. Eleven were non- white and all patients were 
foreign born. Their presentation and clinical course were 
consistent with MTB. Four patients had consolidated lobes 
or segments. Ten patients were treated for MTB alone, one 
was treated for MTB and MAC. Nine of them improved over 
6 months, 1 was lost to follow-up and 2 patients died of 
unrelated causes. 
  For the PF study (see Table 1). seven of the ten patients 
were men, six were ex-smokers and four were lifetime non-
smokers.
 Their age range was 49 to 81 years old and BMI 
range 21 to 29. At the time of post-treatment PFTs the 
patients had negative sputum cultures for MAC. All the 
patients were followed for negative cultures on a monthly 
basis. For FEV1, 9 patients had increases
 from 2 to 17% or 
no change; 1 patient had a decrease of 9%. For FVC, 7 
patients had increases from 4 to 17%, 3 had a decrease from 
3 to 11%. For FEV1/FVC, 7 patients had increases from 5 to 
13% or no change,
 3 had a decrease, 1% to 3%; included in 
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these three was the patient who did not complete therapy. 
For 3 patients, DLCO increased by
  4% to 27% (mean 
change, 16%) and in 2 patients it decreased by 5% and 8%, 
(mean change, 7%). TLC increased in all 5 patients tested, 
by 3% to 9%. In 3 patients, FRC% decreased
 by 9%, 21% 
and 25% (mean change, 18%) and in 2 patients it increased 
by 4% and 31% (mean change, 18%). 
 
Fig. (2). Computer tomography scan of chest from an 84-year-old 
woman with one-year history of cough and dyspnea. Note multiple 
peripheral nodules and an ill-defined pleural-based density in the 
superior segment of the right lower lobe and several small nodules 
in the periphery of the left lower lobe. 
 
Fig. (3). Computer tomography scan of chest from a 75-year-old 
woman with two-year history of productive cough. Note multiple 
bilateral nodules. 
  Eight (8) patients had abnormal PF to begin with and 
these
  had mean increases (percent predicted values) and p 
values as follows: FEV1 of 10.29±4.72, 0.001; FVC of 
10.86±5.34, 0.09 and FEV1/FVC of7.67
  ±3.50, 0.42. Two 
(2) patients had normal PF and these had minimal change in 
FEV1,
 FVC and FEV1/FVC. 
DISCUSSION 
  We found that MAC lung infection was more prevalent 
in our institution, consisting of two inner city community 
hospitals, than we had believed [10]. Until these studies, we 
thought that MAC lung disease was less frequent than 
pulmonary tuberculosis. This was believed because the 
results of MAC positive cultures were only made available 
to the patient’s PMD and since only the PMD was informed  
of MAC, he/she was likely to ignore/consider this 
unimportant unless  the PMD was a pulmonolgist If the 
primary physician was a pulmonologist the pulmonary 
department was informed about the results. On the other 
hand, in the case of positive results for MTB the pulmonary 
department was informed regardless of PMD. During the one 
year period constituting the first study, there were 15 
confirmed cases of active pulmonary tuberculosis, 5 of them 
in immunocompetent patients; it was a surprise to us to find 
21 cases of likely MAC lung infection in non-
immunocompromised persons during the same twelve 
months. This incidence is about 4 times greater than the 
incidence of tuberculosis. Moreover, the true incidence may 
be underestimated, as a significant number of patients with 
active MAC do not have sputa sent for AFB because of low 
clinical suspicion and lack of pulmonary consultation. We 
can only speculate whether these observations can be 
extrapolated to previous years. We believe our findings 
apply to other hospitals with similar patient mix; many of 
our patients present to or attend clinics at a number of 
hospitals in the borough of Queens. 
  We believe it is important to note that if a pulmonologist 
was not directly involved in the patient’s care, the possibility 
of MAC lung disease was not considered The non-
pulmonologist PMDs were treating the patients for 
pneumonia. The pulmonary/infectious disease departments 
were not initially involved. If the patients were referred by 
the non-pulmonologist PMDs to the institution pulmonary 
clinic or private pulmonologist the diagnosis of MAC 
infection was made. This observation points to the need to 
educate internists and family physicians about this 
increasingly diagnosed disease that is capable of causing 
permanent lung damage and even fatality when untreated. 
With greater awareness, sputa will be evaluated for AFB and 
pulmonary consultation called to patients with clinical or 
radiographic abnormalities consistent with MAC. It has been 
known that MAC lung infection should be considered in 
middle- aged and elderly patients, especially those with pre-
existing lung disease [5]. Emphasis on ethnic or national 
origin (white, U.S.-born) and smoking status appears less 
important than formerly thought. The findings that half of 
our patients were white and U.S. born is nevertheless 
noteworthy because our hospitals serve a diverse patient 
population including a majority of foreign-born, black, Asian 
and Hispanic patients. 
  Reasons to explain the prevalence of MAC disease in 
immunocompetent individuals may include reduced 
immunity to mycobacteria in the population because of the 
reduced prevalence of MTB infection and Bacillus Calmette-
Guerin (BCG) vaccination and greater exposure to 
nontuberculous mycobacteria, primarily MAC, due to 
changes in personal hygiene habits from bathing to 
showering [11, 12]. MAC is present in tap water and 
becomes aerosolized by showerheads. We have no 
information about BCG vaccinations or whether our patients 
showered instead of taking baths; use of hot tubs or 
gardening, which may be risk factors for MAC infection, 
were unlikely in this population. There is no documentation 
in the literature of human-to-human transmission of MAC 
lung disease. It is believed that all cases result from 
environmental exposure. Smoking was a risk factor, possibly  
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making the patient more susceptible to infection because of 
impairment of bronchial clearance mechanisms, underlying 
lung damage from smoking or the cigarettes serving as a 
source of MAC. 
  The 2007 ATS guidelines, as their predecessors, discuss 
who should be treated for MAC lung disease [7]. The basic 
requirement is at least 2 positive sputum cultures since a 
single positive sputum culture may result from 
environmental contamination. In our experience, however, 
strict application of this guideline is misleading as two of our 
patients had only one sputum culture positive for MAC but 
the clinical presentation and radiographic changes strongly 
Table 1.  PFTs Before and After Anti-MAC Treatment 
 
FEV1 FVC  FEV1/FVC TLC  FRC  DLCO 
Pt RX 
% pd   %  pd   %  pd   %  pd   %  pd  %  pd  
1  post 70  13 80 4  77  11  106  3  134 -21 71  4 
 pre  59   76    66    103    155   67  
                   
2  post 75  13 86 8  71  7 109  6  142 -25 100 16 
 pre  62   78    64    103    167   84  
                   
3 post 87 17  100  15  74  5  132 5 139 -9 106 27 
 pre  70   85    69    127    148   79  
                   
4  post  36  11  75  16  38  5        
  pre  25    59    33         
                   
5  post  62  6  79  5 64  5        
  pre  56    74    59         
                   
6  post  79  9  105  17  64  -3        
  pre  70    88    67         
                   
7  post  88  2  77  -5 84  -1        
  pre  86    82    85         
                   
8  post  79  -9  90  -11  67  0        
  pre  88    101    67         
                   
9  post 66  0  74 3  85  13 85  9  92  31  84  -5 
 pre  66   77    73    73  61  89  
                   
10 post 51  3  77  11  56  -1  144  4  184  4  42  -8 
 pre  48   66    57    140    180   50  
                   
 Mean      10.29    10.86    7.67        
  SD    4.72    5.34   3.50        
  p    0.001    0.09   0.42        
                   
Mean, SD, p values reported for increases in patients with abnormal PFTs. 
Pt = Patient number, RX = Anti-MAC therapy, Post = Post treatment, Pre = Pre-treatmenr, %pd = Percent predicted,  = Change from pre and post values,  = Increase, SD = 
Standard deviation, p = Probability. MAC Lung Disease in Inner City Community Hospitals  The Open Respiratory Medicine Journal, 2010, Volume 4    81 
supported MAC lung disease. At the other end of the 
spectrum, one patient had 5 sputum cultures positive. He was 
treated for community-acquired pneumonia with complete 
clinical and radiographic resolution by the 9
th day. We 
believe he did not have MAC lung disease and the cultures 
represented only colonization of his airways. Based on this 
experience, we strongly believe that clinical-radiographic 
evidence should prevail over the number of positive cultures 
when the indications for treatment for MAC are considered 
culture while another suptum/BAL culture is obtained. 
  MAC lung disease is more prevalent in this patient 
population than we previously believed. Greater awareness 
of this slowly progressive disease is needed. Primary care 
physicians should be alerted to consider MAC as a possible 
etiology for chronic lung disease, perhaps through the 
standard forms used for admission history and diagnosis and 
for physician orders. 
  In our study to evaluate how often MAC and MTB co-
exist we found that 12 patients had combined mycobacterial 
infection compared with 92 who cultured for MAC alone. 
Most patients with combined infection were clinically 
consistent with MTB and responded to anti MTB treatment 
alone. Most patients were non-white; all were foreign-born 
in contrast to our experience with MAC infection alone were 
50% of the patients were white and US born. 
  In our study that evaluated patients who receive anti-
MAC therapy all eight patients who had abnormal PF 
showed increases in FEV1, 90% had an increase in FVC and 
80% had an increase in FEV1/FVC
  ratio. Three of five 
patients had an increase in DLCO. The reported differences 
do not appear to be larger than test variability but were 
consistent in the same direction. This shows that treatment 
with anti-MAC therapy improved PF in those patients whose 
PF was abnormal to begin with.
 
  To the best of our knowledge, these studies were the first 
to evaluate the prevalence and nature of MAC lung disease 
and the questions of co-infection with MTB and PF 
improvements after anti-MAC therapy in inner city 
community hospitals. We believe similar studies are needed 
elsewhere to explore the extent to which our findings can be 
extrapolated to other institutions, geographic areas, and 
patient population groups. 
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